Asia-Pacific
A fresh wave of deals highlights why investors favour IP firms and why independent outfits may soon have to rethink their strategy
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Law firms across the world are seemingly united in their reluctance to give juniors a chance, which shouldn’t be the case
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry -
Sponsored by Tilleke & GibbinsSuebsiri Taweepon of Tilleke & Gibbins highlights a critical issue in Thailand’s copyright regime while examining the legal uncertainties, licensing burdens, and data-scraping risks in AI development
-
Sponsored by Remfry & SagarSonal Goel of Remfry & Sagar says two recent rulings show Indian courts’ evolving approach to tackling online counterfeiting, impersonation, and trademark misuse through dynamic, dynamic+, and superlative injunctions
-
Sponsored by Liu, Shen & AssociatesRan Wang of Liu, Shen & Associates outlines the guidance the cited cases offer on issues such as patent evaluation reports, infringement judgments after invalidation, use environment features, and amendment rules
-
Sponsored by Bird & BirdSeiko Hidaka of Bird & Bird and Kento Sumi, currently seconded to Bird & Bird, analyse a landmark decision in a standard-essential patent case and its implications for licensing practices and future litigation in Japan
-
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
